{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:03:42Z","timestamp":1789711422174,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.leukres.2011.01.033","type":"journal-article","created":{"date-parts":[[2011,3,8]],"date-time":"2011-03-08T06:48:48Z","timestamp":1299566928000},"page":"921-931","source":"Crossref","is-referenced-by-count":13,"title":["Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid"],"prefix":"10.1016","volume":"35","author":[{"given":"Francesca","family":"Buchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Pastorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germano","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Gozzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sassolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Tombaccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.01.033_bib0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2011.01.033_bib0010","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2011.01.033_bib0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1586\/14737140.8.1.99","article-title":"Targeted therapy in chronic myeloid leukemia","volume":"8","author":"Jabbour","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.leukres.2011.01.033_bib0020","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr\u2013Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.01.033_bib0025","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr\u2013Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.01.033_bib0030","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR\u2013ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.01.033_bib0035","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-06-1863","article-title":"Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer","volume":"13","author":"Solit","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.01.033_bib0040","doi-asserted-by":"crossref","first-page":"10536","DOI":"10.1158\/0008-5472.CAN-05-1799","article-title":"Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin","volume":"65","author":"Guo","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.01.033_bib0045","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.01.033_bib0050","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.leu.2403764","article-title":"Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR\u2013ABL\u2014inhibition of P-glycoprotein function by 17-AAG","volume":"19","author":"Radujkovic","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.01.033_bib0055","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4161\/cc.6.18.4722","article-title":"Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR\u2013ABL resistant to kinase inhibitors","volume":"6","author":"Peng","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.leukres.2011.01.033_bib0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/138920007780655397","article-title":"Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application","volume":"8","author":"Santini","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.leukres.2011.01.033_bib0065","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.01.033_bib0070","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.01.033_bib0075","first-page":"169","article-title":"The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr\u2013abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines","volume":"15","author":"Xu","year":"2005","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.leukres.2011.01.033_bib0080","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/pr0603708","article-title":"Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance","volume":"6","author":"Ferrari","year":"2007","journal-title":"J Proteome Res"},{"key":"10.1016\/j.leukres.2011.01.033_bib0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0609.2009.01242.x","article-title":"Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro","volume":"83","author":"Kircher","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2011.01.033_bib0090","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/cncr.21725","article-title":"Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells","volume":"106","author":"Morotti","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.01.033_bib0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pmic.200300671","article-title":"Identification of apoptotic tyrosine-phosphorylated proteins after etoposide or retinoic acid treatment","volume":"4","author":"Navakauskiene","year":"2004","journal-title":"Proteomics"},{"key":"10.1016\/j.leukres.2011.01.033_bib0100","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","article-title":"Inhibition of the ABL kinase activity blocks the proliferation of BCR\/ABL+ leukemic cells and induces apoptosis","volume":"23","author":"Gambacorti-Passerini","year":"1997","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.leukres.2011.01.033_bib0105","first-page":"822","article-title":"Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics","volume":"15","author":"Seigneurin","year":"1987","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2011.01.033_bib0110","first-page":"3603","article-title":"Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase","volume":"53","author":"Beran","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.01.033_bib0115","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR\u2013ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.01.033_bib0120","first-page":"5995","article-title":"Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line","volume":"62","author":"Ricci","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.01.033_bib0125","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/0008-5472.CAN-04-3011","article-title":"Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells","volume":"65","author":"Bug","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.01.033_bib0130","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/1522-2683(200105)22:9<1686::AID-ELPS1686>3.0.CO;2-L","article-title":"Two-dimensional electrophoresis and peptide mass fingerprinting of bacterial outer membrane proteins","volume":"22","author":"Molloy","year":"2001","journal-title":"Electrophoresis"},{"key":"10.1016\/j.leukres.2011.01.033_bib0135","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1038\/sj.onc.1207788","article-title":"Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12","volume":"23","author":"Huang","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2011.01.033_bib0140","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood.V98.13.3864","article-title":"Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells","volume":"98","author":"Tipping","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.01.033_bib0145","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","author":"Steinberg","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.leukres.2011.01.033_bib0150","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1053\/j.seminhematol.2006.12.003","article-title":"New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance","volume":"44","author":"Jabbour","year":"2007","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2011.01.033_bib0155","first-page":"208","article-title":"An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"116","author":"Gambacorti-Passerini","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2011.01.033_bib0160","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molcel.2005.06.030","article-title":"Structural basis for the cytoskeletal association of Bcr\u2013Abl\/c-Abl","volume":"19","author":"Hantschel","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.leukres.2011.01.033_bib0165","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1158\/1535-7163.MCT-09-0936","article-title":"Expression of oncogenic kinase Bcr\u2013Abl impairs mitotic checkpoint and promotes aberrant divisions and resistance to microtubule-targeting agents","volume":"9","author":"Wolanin","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2011.01.033_bib0170","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/0008-5472.CAN-09-2181","article-title":"Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536","volume":"70","author":"Gleixner","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.01.033_bib0175","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1021\/pr0704128","article-title":"Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines","volume":"6","author":"Fontana","year":"2007","journal-title":"J Proteome Res"},{"key":"10.1016\/j.leukres.2011.01.033_bib0180","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.bbapap.2006.02.004","article-title":"Altered protein profile in chronic myeloid leukemia chronic phase identified by a comparative proteomic study","volume":"1764","author":"Pizzatti","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2011.01.033_bib0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bcmd.2006.08.001","article-title":"The proteomic study of sodium butyrate antiproliferative\/cytodifferentiation effects on K562 cells","volume":"37","author":"Grebenova","year":"2006","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.leukres.2011.01.033_bib0190","first-page":"853","article-title":"The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr\/Abl-positive cell lines sensitive and resistant to imatinib mesylate","volume":"88","author":"Gatto","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.01.033_bib0195","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","article-title":"Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia","volume":"104","author":"Baccarani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.01.033_bib0200","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr\u2013Abl-expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.01.033_bib0205","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr\u2013Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.leukres.2011.01.033_bib0210","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/jmbi.2000.3687","article-title":"Protein-protein interaction among hnRNPs shuttling between nucleus and cytoplasm","volume":"298","author":"Kim","year":"2000","journal-title":"J Mol Biol"},{"key":"10.1016\/j.leukres.2011.01.033_bib0215","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1128\/MCB.22.7.2255-2266.2002","article-title":"hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR\/ABL leukemogenesis","volume":"22","author":"Iervolino","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.leukres.2011.01.033_bib0220","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2005-09-3732","article-title":"A MAPK\/HNRPK pathway controls BCR\/ABL oncogenic potential by regulating MYC mRNA translation","volume":"107","author":"Notari","year":"2006","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T05:40:41Z","timestamp":1592372441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0145212611000609"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.01.033","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}